Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Hold” from Analysts

Altimmune, Inc. (NASDAQ:ALT) has received a consensus recommendation of “Hold” from the nine analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.60.

A number of analysts have recently issued reports on ALT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. B. Riley Financial reduced their price objective on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Barclays began coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th.

Insider Activity

In other Altimmune news, CEO Jerome Benedict Durso acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $3.54 per share, with a total value of $70,800.00. Following the purchase, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Gill bought 12,500 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 55,527 shares of company stock valued at $213,778. 4.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Altimmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. increased its stake in shares of Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the last quarter. Concurrent Investment Advisors LLC grew its holdings in shares of Altimmune by 10.4% in the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after purchasing an additional 2,500 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after purchasing an additional 2,748 shares during the period. Finally, Deutsche Bank AG increased its position in Altimmune by 4.0% during the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after purchasing an additional 3,047 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Stock Down 5.3%

ALT opened at $3.60 on Friday. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73. The company has a quick ratio of 17.18, a current ratio of 18.55 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $4.50 and a 200 day moving average price of $4.29. The company has a market cap of $468.25 million, a PE ratio of -3.56 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Sell-side analysts expect that Altimmune will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.